The cost of hepatitis C and the cost-effectiveness of its prevention

By Shiell A.   Law M.G.  

Health Policy, Vol. 58, Iss. 2, 2001-11 ,pp. : 121-131

Elsevier

Access to resources Recommend Favorite

Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease?

By Lindholm L.   Hallgren C.-G.   Boman K.   Markgren K.   Weinehall L.   Ogren J.-E.  

Health Policy, Vol. 48, Iss. 3, 1999-08 ,pp. : 155-170

Elsevier

Access to resources Recommend Favorite

Lipid-Lowering Medication for Secondary Prevention of Coronary Heart Disease in a German Outpatient Population: The Gap Between Treatment Guidelines and Real Life Treatment Patterns

By Ruof J.   Klein G.   März W.   Wollschläger H.   Neiss A.   Wehling M.  

Preventive Medicine, Vol. 35, Iss. 1, 2002-07 ,pp. : 48-53

Academic Press

Access to resources Recommend Favorite

Cost-effectiveness of hepatitis A vaccine in prevention of secondary hepatitis A infection

By Pechevis M.   Khoshnood B.   Buteau L.   Durand I.   Piquard Y.   Lafuma A.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3556-3564

Elsevier

Access to resources Recommend Favorite

The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand

By Kam L.S.   Devlin N.J.  

Health Policy, Vol. 38, Iss. 2, 1996-11 ,pp. : 101-115

Elsevier

Access to resources Recommend Favorite